Login / Signup

Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses.

Daisuke SugiuraTakumi MaruhashiIl-Mi OkazakiKenji ShimizuTakeo K MaedaTatsuya TakemotoTaku Okazaki
Published in: Science (New York, N.Y.) (2019)
Targeted blockade of PD-1 with immune checkpoint inhibitors can activate T cells to destroy tumors. PD-1 is believed to function mainly at the effector, but not in the activation, phase of T cell responses, yet how PD-1 function is restricted at the activation stage is currently unknown. Here we demonstrate that CD80 interacts with PD-L1 in cis on antigen-presenting cells (APCs) to disrupt PD-L1/PD-1 binding. Subsequently, PD-L1 cannot engage PD-1 to inhibit T cell activation when APCs express substantial amounts of CD80. In knock-in mice in which cis-PD-L1/CD80 interactions do not occur, tumor immunity and autoimmune responses were greatly attenuated by PD-1. These findings indicate that CD80 on APCs limits the PD-1 coinhibitory signal, while promoting CD28-mediated costimulation, and highlight critical components for induction of optimal immune responses.
Keyphrases
  • immune response
  • nk cells
  • type diabetes
  • multiple sclerosis
  • induced apoptosis
  • drug delivery
  • adipose tissue
  • cell death
  • signaling pathway
  • inflammatory response
  • regulatory t cells
  • case report
  • cancer therapy
  • pi k akt